Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096005 · ClinicalTrials.gov registry record · Phase 1
Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00096005: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00096005 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096005, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin, work in different ways to stop cancer cells from dividing so they stop growing or die. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of tanespimycin by making cancer cells more sensitive to the drug. Combining tanespimycin with bortezomib may kill more cancer cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
- DRUG tanespimycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096005
The ClinicalTrials.gov registry entry for NCT00096005 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00096005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096005 about?
NCT00096005 is a clinical study titled "Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas". This phase I trial is studying the side effects and best dose of giving tanespimycin together with bortezomib in treating patients with advanced solid tumors or lymphomas. (Accrual for lymphoma patients closed as of 11/27/09) Drugs used in chemotherapy, such as tanespimycin, work in different ways t...
What is the current status of trial NCT00096005?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00096005?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG), tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00096005?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.